Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06465966 · ClinicalTrials.gov registry record · NA

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

A NA study of Prostate Cancer, sponsored by University of Florida.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06465966 is a NA study of Prostate Cancer that is actively recruiting participants, run by University of Florida. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06465966, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the use of ionizing-radiation photo acoustic imaging (iRAI) for proton radiation treatment.

Conditions Studied

Interventions

  • DEVICE iRAI

Study Locations (1)

Florida

  • Univeristy of Florida Health Proton Therapy Institute - Jacksonville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-09-23
Est. Completion 2027-10-01
Phase NA

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT06465966

The ClinicalTrials.gov registry entry for NCT06465966 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which iRAI is the first listed.

NCT06465966 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06465966 about?

NCT06465966 is a clinical study titled "UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning". The purpose of this study is to evaluate the use of ionizing-radiation photo acoustic imaging (iRAI) for proton radiation treatment.

What is the current status of trial NCT06465966?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-23. Estimated completion is 2027-10-01.

What conditions does trial NCT06465966 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06465966?

The interventions under investigation include: iRAI (DEVICE).

Who is sponsoring clinical trial NCT06465966?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06465966 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.